In addition to being used for the treatment of cancer, drug Zaltrap ( aflibercept ) is also potentially be benefits to cope with diabetes , according to a new study published in the journal Nature Medicine.
Researchers say they have identified a molecular pathway or a series of interactions between proteins involved in the progression of diabetes . And it turns out , the track can be adjusted by the Zaltrap drug against cancer.
Zaltrap is a drug that has been approved in the United States and several other countries to treat advanced colorectal cancer and macular degeneration of the wet type . This drug can inhibit the vascular vessel endothelial growth factor (VEGF ), which blocks the growth of blood vessels in the tumor cells . This is what makes the cells become starved of oxygen and eventually die .
Once identified, the researchers found there are some series that connects the VEGF inhibitor protein and sugar levels in the blood.
Study researchers, Amato Giaccia , professor of cancer biology and director of radiation oncology at Stanford University School of Medicine said, proteins involved in this pathway can be used as a target for the development of a new treatment treatment of diabetes.
" We were surprised by the finding that a drug commonly used for cancer was found to have beneficial effects on diebetes ," said another researcher , Dr. Calvin Kuo, professor of medicine at the same university.
However, he added , this study was conducted in mice and often failed the test in humans. Therefore, more research is needed to confirm this.
The researchers say , VEGF inhibitors indicated that Zaltrap can affect blood sugar levels in the blood, but there is no evidence in research on humans.